Skip to main content
IMMX
NASDAQ Life Sciences

Immix Posts Q3 Loss, $340.9M Cash Into Mid-2028, Adds Two Commercial Leads

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$8.07
Mkt Cap
$669.027M
52W Low
$3.26
52W High
$15.1
52W Position info
148% above low
Off High info
47% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

IMMX has more than doubled off its 52-week low of $3.26.

Summary

Immix reported a $13.9 million third-quarter net loss and $340.9 million in cash and marketable securities, which management expects to fund operations into mid-2028. It also named two senior commercial/regulatory leaders and set an ASH oral presentation of NEXICART-2 interim data for December 14, 2026.


Key Events · Earnings and Guidance · IMMX

  • Q3 Loss of $13.9M on $15.9M Spend

    Third-quarter operating expenses were $15.9 million, of which $5.5 million R&D and $10.4 million G&A, producing a $13.9 million net loss.

  • Cash of $340.9M Funds Into Mid-2028

    Cash, cash equivalents and marketable securities reached $340.9 million at September 30, 2026, up from $234.1 million at June 30, and management expects runway into mid-2028.

  • Two Senior Commercial-Stage Hires

    David He, MD, PhD joined as SVP, Head of Technical Operations, and Karin McIntosh as SVP, Head of Regulatory Affairs, alongside additional commercial, regulatory, quality and medical affairs staff.

  • ASH Oral Presentation December 14, 2026

    Interim NEXICART-2 clinical data will be presented orally at the 68th ASH Annual Meeting in New Orleans on December 14, 2026; the company also presents at the J.P. Morgan Healthcare Conference January 11-14, 2027.


Analysis · IMMX · Life Sciences

The quarter itself is unremarkable — $15.9 million of operating spend and a $13.9 million net loss — but the balance sheet is the story: $340.9 million in cash and marketable securities at September 30 is expected to fund operations into mid-2028, comfortably past the planned mid-2027 BLA submission and the first-half 2027 NEXICART-3 front-line trial start. That removes any near-term financing need, which matters because the company already raised $125 million at $11.00 per share in September. The two senior hires — a head of technical operations who worked on two approved BCMA CAR-Ts and a regulatory head with multiple FDA approvals — are the concrete steps behind the commercial launch preparation. The next hard data point is the interim NEXICART-2 oral presentation at ASH on December 14, 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IMMX was trading at $8.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $669M. The 52-week trading range was $3.26 to $15.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IMMX - Latest Insights

IMMX
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $8.07
Real-time Price: $8.24 info
Change: +$0.170 (+2%) info
Market Cap: $669.027M info
IMMX
Sep 30, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.40
Real-time Price: $8.24 info
Change: -$2.16 (-21%) info
Market Cap: $669.027M info
IMMX
Sep 29, 2026, 7:22 AM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $12.15
Real-time Price: $8.24 info
Change: -$3.91 (-32%) info
Market Cap: $669.027M info
IMMX
Sep 29, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $8.24 info
Change: -$3.34 (-29%) info
Market Cap: $669.027M info
IMMX
Aug 07, 2026, 5:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $9.81
Real-time Price: $8.24 info
Change: -$1.57 (-16%) info
Market Cap: $669.027M info